GlaxoSmithKline Pharmaceuticals Limited has announced significant leadership changes with the appointment of Ronojit Biswas as the new Whole-Time Director and Chief Financial Officer. The Board of Directors approved this appointment during their meeting held on March 2, 2026, marking a strategic transition in the company's senior management.

Leadership Transition Details

The Board meeting, which commenced at 11:00 am and concluded at 12:00 noon, approved Biswas's appointment for a three-year term effective April 1, 2026. This appointment comes as part of a planned leadership transition, with current CFO Juby Chandy stepping down from his roles as Whole-Time Director and CFO on March 11, 2026.

Professional Background and Experience

Ronojit Biswas brings extensive experience to his new role, having spent over 25 years with GSK across various international markets. His career journey with the company began in India as a Management Trainee in 1999, and he has since held several senior global and regional leadership positions spanning India, Vietnam, Singapore, Brazil, and the UK.

Prior to this appointment, Biswas served as Senior Finance Director – Global Product Strategy, based in Singapore. His diverse experience includes serving as CFO for GSK's Brazil and Vietnam businesses, as well as Regional Controller for GSK's International region, where he led financial reporting and performance management with responsibility for internal controls.

Educational Qualifications

Biswas holds strong academic credentials in finance and management:

• Post Graduate Program in Management (Finance) from Management Development Institute, Gurgaon
• Bachelor's degree in Commerce (Hons.) from St. Xavier's College, Kolkata

Current CFO's New Role

Juby Chandy, the outgoing CFO, will transition to a new leadership position within the GSK Group, focusing on APAC Finance. The company acknowledged Chandy's valuable contributions during his tenure, particularly highlighting his central role in strengthening the company's financial position, improving governance, and delivering on key strategic priorities during the transformation period.

Regulatory Compliance

The appointment announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Biswas is not related to any existing Directors and is not debarred from holding the Office of Director by any regulatory authority.

This leadership transition represents continuity in GSK Pharmaceuticals' strategic direction while bringing fresh perspective through Biswas's extensive international experience and deep understanding of the company's global operations.

GlaxoSmithKline Pharmaceuticals Limited has disclosed to stock exchanges that the Directorate of Revenue Intelligence conducted a search at its registered office in Mumbai. The pharmaceutical company made this disclosure under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

Search Details and Timeline

The search was initiated by the Directorate of Revenue Intelligence, Department of Revenue, Government of India, under the provisions of Section 105 of the Customs Act, 1962. The proceedings began on February 27, 2026, and were completed on February 28, 2026.

Company Response and Operations

GlaxoSmithKline Pharmaceuticals stated that company officials extended full cooperation to the department and responded to all queries raised during the search. The company emphasized that its business operations continue as usual without any disruption.

Regulatory Compliance

The disclosure was made in compliance with regulatory requirements, with the company informing both BSE Limited and the National Stock Exchange of India Limited about the proceedings. The company confirmed that the search has been completed and there is no impact on its financial, operational, or other activities.

The communication was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, on February 28, 2026, ensuring timely disclosure to stakeholders and regulatory authorities.